Furthermore, the addition of immune checkpoint inhibitors, such as anti–PD‐L1 antibodies, further enhances the anti‐tumor immune response by blocking the interaction between PD‐L1 on tumor cells and PD‐1 on T cells. This evidence concerns the gene CD274 and neoplasm.